Search Results - "DEPENBROCK, H"

Safety and Efficacy of Necitumumab (N) During Single-Agent Treatment to Progression Following Gemcitabine-Cisplatin (GC) Chemotherapy Plus Necitumumab (IMC-11F8/LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (sq-NSCLC) (SQUIRE) by Socinski, M.A, Thatcher, N, Luft, A.V, Szczesna, A, Ciuleanu, T, Szafrański, W, Ramlau, R, Bálint, B, Kazarnowicz, A, Molinier, O, Depenbrock, H, Nanda, S, Obasaju, C, Paz-Ares, L

Get full text

Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial by Boeck, S, Weigang-Köhler, K, Fuchs, M, Kettner, E, Quietzsch, D, Trojan, J, Stötzer, O, Zeuzem, S, Lordick, F, Köhne, C-H, Kröning, H, Steinmetz, T, Depenbrock, H, Heinemann, V

“…Background: A standard second-line chemotherapy regimen has yet to be defined for patients with gemcitabine (Gem)-refractory advanced pancreatic cancer (PC)…”
Get full text

Clinical and Pharmacokinetic Phase I Study of Multitargeted Antifolate (LY231514) in Combination With Cisplatin by Thödtmann, R, Depenbrock, H, Dumez, H, Blatter, J, Johnson, R D, van Oosterom, A, Hanauske, A R

“…Multitargeted antifolate (MTA; LY231514) has broad preclinical antitumor activity and inhibits a variety of intracellular enzymes involved in the folate…”
Get full text

In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells by DEPENBROCK, H, PETER, R, FAIRCLOTH, G. T, MANZANARES, I, JIMENO, J, HANAUSKE, A. R

“…Aplidine is a new marine anti-cancer depsipeptide isolated from the Mediterranean tunicate Aplidium albicans. We have evaluated its antiproliferative action…”
Get full text

Preclinical activity of trans-indazolium [tetrachlorobisindazoleruthenate(III)] (NSC 666158; IndCR; KP 1019) against tumour colony-forming units and haematopoietic progenitor cells by Depenbrock, H., Schmelcher, S., Peter, R., Keppler, B.K., Weirich, G., Block, T., Rastetter, J., Hanauske, A.-R.

“…Trans-indazolium[tetrachlorobisindazoleruthenate(III)] (KP 1019) is a new heavy metal complex with promising activity against tumour cell lines and in animal…”
Get full text

Preliminary results of a phase I study with MTA (LY231514) in combination with cisplatin in patients with solid tumors by Thödtmann, R, Depenbrock, H, Blatter, J, Johnson, R D, van Oosterom, A, Hanauske, A R

“…MTA (multitargeted antifolate, LY231514) is a novel antimetabolite resulting from structure/activity studies of the lometrexol-type antifolates. It has been…”
Get more information

Preclinical activity of 17β-[N-[N′-(2-chloroethyl)-N′-nitrosocarbamoyl]- l-alanyl]-5α-dihydrotestosterone (E91) against tumour colony forming units and haematopoietic progenitor cells by Rank, P, Peter, R, Depenbrock, H, Eisenbrand, G, Schmid, P, Pitzl, H, Hanauske, A.-R

“…E91 (17β-[N-[N′-(2-chloroethyl)-N′-nitrosocarbamoyl]- l-alanyl]-5α-dihydrotestosterone) (CNC-ala-DHT) is a newly synthesised alkylating compound consisting of…”
Get full text

Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineoplastic agents by Vogel, M, Hilsenbeck, S G, Depenbrock, H, Danhauser-Riedl, S, Block, T, Nekarda, H, Fellbaum, C, Aapro, M S, Bissery, M C, Rastetter, J

“…Taxotere (TER) and taxol (TA) are new antitumour agents currently undergoing clinical evaluation. We studied the antineoplastic effects of these agents (final…”
Get more information

Subgroup Analysis of Elderly Patients in Squire: a Randomized, Multicenter, Open-Label, Phase Iii Study of Necitumumab (N) Plus Gemcitabine-Cisplatin (GC) Chemotherapy Versus Gc Alone in First-Line Treatment of Patients (PTS) with Stage Iv Squamous Non-Small Cell Lung Cancer (SQ-NSCLC) by Thatcher, N., Ciuleanu, T.-E., Ramlau, R., Schumann, C., Paz-Ares, L., Depenbrock, H., Nanda, S., Chouaki, N., Socinski, M.

Get full text

436P Efficacy and safety of necitumumab (neci) in East Asian (EA) patients (pts) with stage IV squamous non-small-cell lung cancer (NSCLC): a subanalysis of the SQUIRE trial by Park, K., Cho, E.K., Bello, M., Ahn, M.-J., Thongprasert, S., Song, E.-K., Soldatenkova, V., Depenbrock, H., Puri, T., Orlando, M.

Get full text

SQUIRE: a randomised, multicentre, open-label, phase III study of gemcitabine-cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC); Subgroup efficacy and safety data for pts with epidermal growth factor receptor (EGFR)-expressing tumours by Zilembo, N., Giannetta, L., Crinò, L., Bearz, A., Amoroso, D., Gamucci, T., Buscaglia, M., Tiseo, M., Soldatenkova, V., Chouaki, N., Depenbrock, H., Hirsch, F.R., Paz-Ares, L., Bidoli, P.

Get full text

Effects of the microtubule-disturbing agents docetaxel (Taxotere), vinblastine and vincristine on epidermal growth factor-receptor binding of human breast cancer cell lines in vitro by Hanauske, A R, Depenbrock, H, Shirvani, D, Rastetter, J

“…Epidermal growth factor (EGF) is a mitogenic peptide that binds to surface membrane receptors (EGFR) of breast cancer cells. After binding, secondary…”
Get more information

Gemcitabine and etoposide in small cell lung cancer: phase I and II trials by Rassmann, I, Thödtmann, R, Depenbrock, H, Blatter, J, Gatzemeier, U, Rastetter, J, Hanauske, A R

“…Gemcitabine and etoposide have both shown single-agent activity against multiple tumor types in clinical trials, including small cell lung cancer, but have not…”
Get more information

Interleukin 1 modulates growth of human renal carcinoma cells in vitro by KOCH, I, DEPENBROCK, H, DANHAUSER-RIEDL, S, RASTETTER, J. W, HANAUSKE, A.-R

“…We have investigated the influence of interleukin 1 (IL-1) on growth of human renal carcinoma cells in vitro. Using a capillary soft-agar cloning system, 18%…”
Get full text

Activity of NK 611, a new epipodophyllotoxin derivative, against colony forming units from freshly explanted human tumours in vitro by Hanauske, A.-R., Wüster, K.C., Lehmer, A., Rotter, M., Schneider, P., Kaeser-Fröhlich, A., Rastetter, J., Depenbrock, H.

“…NK 611 is a new semisynthetic analogue of etoposide, which presumably also acts through inhibition of topoisomerase II, and has been found to be more potent…”
Get full text

Safety and Efficacy of Necitumumab (N) During Single-Agent Treatment to Progression Following Gemcitabine-Cisplatin (GC) Chemotherapy Plus Necitumumab (IMC-11F8/LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (sq-NSCLC) (SQUIRE): Metastatic Non-Small Cell Lung Cancer by Socinski, M.A., Thatcher, N., Luft, A.V., Szczesna, A., Ciuleanu, T., Szafrański, W., Ramlau, R., Bálint, B., Kazarnowicz, A., Molinier, O., Depenbrock, H., Nanda, S., Obasaju, C., Paz-Ares, L.

Get full text

Effects of vinorelbine on epidermal growth factor-receptor binding of human breast cancer cell lines in vitro by DEPENBROCK, H, SHIRVANI, A, RASTETTER, J, HANAUSKE, A.-R

“…Epidermal Growth Factor (EGF) is a mitogenic peptide that binds to surface membrane receptors (EGFR) of breast cancer cells. After binding, secondary…”
Get full text

1232PSQUIRE: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III STUDY OF GEMCITABINE-CISPLATIN (GC) CHEMOTHERAPY PLUS NECITUMUMAB (IMC-11F8/LY3012211) VS GC ALONE IN THE FIRST-LINE TREATMENT OF PATIENTS (PTS) WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCER (SQ-NSCLC): UPDATE ON KEY SUBGROUPS by Socinski, M.A., Paz-Ares, L., Luft, A.V., Szczesna, A., Ciuleanu, T.E., Szafranski, W., Reck, M., Balint, B., Park, K., Schumann, C., Hirsch, F.R., Depenbrock, H., Nanda, S., Chouaki, N., Thatcher, N.

“…Abstract Aim: EGFR is detectable in most pts with sq-NSCLC tumors. Efficacy and safety of necitumumab (N), a human IgG1 anti-EGFR monoclonal antibody that…”
Get full text

Squire: a Randomized, Multicenter, Open-Label, Phase III Study of Gemcitabine-Cisplatin (Gc) Chemotherapy Plus Necitumumab (Imc-11F8/Ly3012211) Vs Gc Alone in the First-Line Treatment of Patients (Pts) with Stage Iv Squamous Non-Small Cell Lung Cancer (Sq-Nsclc): Update on Key Subgroups by Socinski, M.A., Paz-Ares, L., Luft, A.V., Szczesna, A., Ciuleanu, T.E., Szafranski, W., Reck, M., Balint, B., Park, K., Schumann, C., Hirsch, F.R., Depenbrock, H., Nanda, S., Chouaki, N., Thatcher, N.

Get full text

Characterization and mutual ligand-induced modulation of epidermal growth factor and interferon-alpha receptors on renal carcinoma cells in vitro by Heise, H, Depenbrock, H, Rastetter, J W, Hanauske, A R

“…We have determined the binding of epidermal growth factor (EGF) and interferon (IFN)-alpha to their specific receptors on four renal carcinoma cell lines…”
Get more information